Quick answer
What is Dulaglutide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Dulaglutide is not a peptide, grouped on this site under Incretin receptor agonists, and the 12 research records kept here are 11 from trials in people and 1 that does not state what kind of study it is.
The literature search returned 1,320 records. This site keeps 12 of them, which is 0.91 per cent of what came back.
What it is
Dulaglutide is indexed here despite not being a peptide, because the same research literature and the same searches cover it. This site puts it in the Incretin receptor agonists group.
A GLP-1 receptor agonist fusion protein; the retrieved records are clinical trials in type 2 diabetes rather than receptor pharmacology.[1, 2]
Taken from the cited 2019 Lancet REWIND and 2014 Lancet AWARD-6 titles together with the class definition.
What kind of records
No public chemistry record was found under this name, so the entry describes a preparation, a protein or a mixture rather than one defined molecule.
That sentence is produced by counting, not by reading. What was counted: PubChem returned no compound record for this name, so the subject is a preparation, protein or mixture rather than a defined small molecule; identity fields are unsourced.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 1,308 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet (London, England) (2019). pmid:31189511
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet (London, England) (2014). pmid:25018121